13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • APOLLO-1

    Acronym: 

    APOLLO-1

    ACTRN/NCT /ethics: 

    NCT03053466

    Scientific title: 

    A phase 1/2 open label, multi-center dose escalation and expansion study of combination immunotherapy CBT-501 (anti-PD-1) or nivolumab with CBT- 101 (c-Met inhibitor) in locally advanced or metastatic hepatocellular

    Summary of trial and patient characteristics

    Cancer Type Liver, Kidney
    Trial Type Treatment
    Phase Phase I, Phase II Tumour Stream Solid Tumors
    Age Range 18 years and older Cancer Stage Locally Recurrent or Locally Advanced, Metastatic or Widespread
    Sex Both Anticipated Start Date 2017-03-27
    Molecular Target Anticipated End Date 2021-12-01
    Cancer Type Liver, Kidney
    Trial Type Treatment
    Phase Phase I, Phase II
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Solid Tumors
    Cancer Stage Locally Recurrent or Locally Advanced, Metastatic or Widespread
    Anticipated Start Date 2017-03-27
    Anticipated End Date 2021-12-01

    Trial Summary

    A phase 1/2 open label, multi-center dose escalation and expansion study of combination immunotherapy CBT-501 (anti-PD-1) or nivolumab with CBT- 101 (c-Met inhibitor) in locally advanced or metastatic hepatocellular carcinoma and renal cell carcinoma

    Lay Summary

    A phase 1/2 open label, multi-center dose escalation and expansion study of combination immunotherapy CBT-501 (anti-PD-1) or nivolumab with CBT- 101 (c-Met inhibitor) in locally advanced or metastatic hepatocellular

    Sponsor / Cooperative group

    Apollomics

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Ashford Cancer Centre Research Sue Yeend syeend@adelaidecancercentre.com.au 08 8292 2240 Dr Amy Hsieh Recruiting